▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3506 by analyst upside · 2026-11-12
INCY
Incyte Corporation
Healthcare · Market Cap $25B · P/E 61.4x
ANALYST PRICE TARGET
+7.5%
implied upside to consensus target
Current Price $122.27
Consensus Target $131.5
Bull Target $157.0
Bear Target $100.0
Analysts Covering 24
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
9
Hold
12
Sell
1
52-Week Low $89.25
52-Week High $132.6
YTD Return +20.6%
FUNDAMENTALS
Market Cap $25B
P/E Ratio (TTM) 61.4x
Forward P/E 14.2x
EPS (TTM) $1.99
PEG Ratio 10.82
Dividend Yield N/A
Revenue (TTM) $6.0B
Profit Margin 6.7%
52-WEEK RANGE
52-Week Low $89.25
52-Week High $132.6
Current Price $122.27
Bear Target $100.0
Bull Target $157.0
● Now $122.27 ● Target $131.5
TRADING DATA
Avg Volume 1.6M
YTD Return +20.6%
Analyst Count 24
Consensus Buy
Upside to Target +7.5%
Last Updated 2026-11-12

ANALYST SUMMARY

Incyte Corporation (INCY) is currently trading at $122.27 with a Wall Street consensus price target of $131.5, implying potential upside of 7.5% over the next 12 months. 24 analysts currently cover INCY, with a consensus rating of Buy - 46% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $157.0, while the most cautious has a target of $100.0.

INCY operates in the Healthcare sector with a market capitalisation of $25B. The stock is up 20.6% year-to-date and is currently trading near the upper end of its 52-week range of $89.25 – $132.6.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for INCY, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Leerink Partners - Reiterated
Outperform → Outperform 2026-11-05 29% win rate (7 calls)
Bernstein - Reiterated
Market Perform → Market Perform 2026-11-02 Building track record
Wells Fargo - Reiterated
Equal-Weight → Equal-Weight 2026-10-30 Building track record
RBC Capital - Reiterated
Sector Perform → Sector Perform 2026-10-30 Building track record
Barclays - Reiterated
Overweight → Overweight 2026-10-30 Building track record
Evercore ISI Group - Reiterated
In-Line → In-Line 2026-10-30 Building track record
Oppenheimer ↑ Upgrade
Perform → Outperform 2026-10-30 14% win rate (7 calls)
TD Cowen - Reiterated
Buy → Buy 2026-10-21 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
53
out of 100
Coverage depth
25/30
Consensus clarity
21/30
Vote unanimity
5/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →